First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients
- This topic has 0 replies, 1 voice, and was last updated 3 years, 1 month ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
https://meetinglibrary.asco.org/record/201202/abstract
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.